ADC Therapeutics SA Current Accrued Expenses And Other Current Liabilities
ADC Therapeutics SA (ADCT) had Current Accrued Expenses And Other Current Liabilities of $53.48 million as of 2023-09-30, per its 6-K filed 2023-11-07.
Discontinued › Notes
ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities · last filed 2023-11-07
- 2023-09-30: Current Accrued Expenses And Other Current Liabilities $53.48M.
- 2023-06-30: Current Accrued Expenses And Other Current Liabilities $53.40M.
- 2023-03-31: Current Accrued Expenses And Other Current Liabilities $57.41M.
- 2022-12-31: Current Accrued Expenses And Other Current Liabilities $73.03M.
| Period end | Current Accrued Expenses And Other Current Liabilities |
|---|---|
| 2023-09-30 | $53.48M 6-K · filed 2023-11-07 |
| 2023-06-30 | $53.40M 6-K · filed 2023-08-08 |
| 2023-03-31 | $57.41M 6-K · filed 2023-05-09 |
| 2022-12-31 | $73.03M 6-K · filed 2023-11-07 |
| 2022-09-30 | $62.66M 6-K · filed 2022-11-08 |
| 2022-06-30 | $52.38M 6-K · filed 2022-08-09 |
| 2022-03-31 | $40.41M 6-K · filed 2022-05-09 |
| 2021-12-31 | $50.50M 20-F · filed 2023-03-15 |
| 2021-09-30 | $39.69M 6-K · filed 2021-11-02 |
| 2021-06-30 | $29.45M 6-K · filed 2021-08-03 |
| 2021-03-31 | $25.27M 6-K · filed 2021-05-06 |
| 2020-12-31 | $30.38M 20-F · filed 2022-03-17 |
| 2019-12-31 | $15.43M 20-F · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |